1 Jun 2014

Research highlights

ARS cover image is by
Dr Devy Deliyanti, one
of the paper's authors
Effective preventive therapies for retinopathy of prematurity (ROP) don't exist, yet globally, there are at least 50,000 children blind from ROP. ProfessorJennifer Wilkinson-Berkain the Department of Immunology leads research efforts into understanding the problem. A recently published paper shows that one form of a particular enzyme complex called NADPH oxidase (NOX) is involved in the development of retinopathy. The research indicates that blocking the action of NOX1 prevents the damage from occurring. Reference:NADPH Oxidase, NOX1, Mediates Vascular Injury in Ischemic Retinopathy. Antioxidants & Redox Signaling. V 20, No 17, 2014 DOI: 10.1089/ars.2013.5357

Anaesthetic nitrous oxide no longer an enigma: results of international trial announced
Video of Paul Myles
describing ENIGMA-II
The ANZCA Trials Group recently announced the much anticipated results of the ENIGMA-II trial. Professor Paul Myles, Director of Anaesthesia and Perioperative Medicine at Alfred Hospital and the Monash department of the same name within Central Clinical School, presented the results at the combined plenary session at the Australian and New Zealand College of Anaesthetist (ANZCA) ASM and Royal Australian College of Surgeons (RACS) ASC on May 6, 2014. Verdict: Nitrous oxide is safe.